tradipitant
Small moleculeapprovedCOVID-19
Approved
Dec 30, 2025
Tradipitant is an experimental drug that is a neurokinin 1 antagonist. It works by blocking substance P, a small signaling molecule. Originally, this compound was owned by Eli Lilly and named LY686017. VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012. — Wikipedia
Clinical trial activity
21 trials · 5 clinical orgs · 1 marketing orgs
Phase 1
3
Phase 2
17
Phase 3
8
Phase 4
0
Earliest trial started Dec 1, 2004 (NCT00191022)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
2010s
- Jan 1, 2013
Vanda Pharmaceuticals — Earliest Phase 1 Sponsor(trial)
- Jan 1, 2018
Vanda Pharmaceuticals — Earliest Phase 3 Sponsor(trial)
2020s
- Dec 30, 2025
Earliest FDA Approval
- Dec 30, 2025
Vanda Pharmaceuticals — Marketing Organization
Indications
Approved for
Mechanism of action
- Neurokinin 1 receptorANTAGONIST
TACR1 antagonist
Approval history
- approvedDec 30, 2025
Chemistry & pharmacology
Loading structure…
SMILES
O=C(c1ccccc1Cl)c1cccnc1-c1nnn(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1-c1ccncc1- Mol. weight
- 587.91 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTradipitant ↗
- ChEMBLCHEMBL3544984 ↗
Also known as
- ly686017
- ly686017
- ly-686017
- ly-686017
- tradipitant
- tradipitant
- tradipitant
- tradipitant
- vly-686
- vly-686
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06804603 | Phase 2 | Feb 25, 2025 | Vanda Pharmaceuticals |
| NCT06836557 | Phase 3 | Jan 9, 2024 | Vanda Pharmaceuticals |
| NCT05903924 | Phase 3 | Jun 30, 2023 | Vanda Pharmaceuticals |
| NCT06138613 | Phase 3 | Feb 27, 2023 | Vanda Pharmaceuticals |
| NCT05653310 | Phase 2 | Dec 31, 2022 | Mayo Clinic, Vanda Pharmaceuticals |
| NCT04849559 | Phase 1 | Feb 1, 2021 | Mayo Clinic, Vanda Pharmaceuticals |
| NCT04326426 | Phase 3 | Apr 13, 2020 | Vanda Pharmaceuticals |
| NCT04327661 | Phase 3 | Feb 26, 2020 | Vanda Pharmaceuticals |
| NCT04140695 | Phase 3 | Oct 21, 2019 | Vanda Pharmaceuticals |
| NCT04028492 | Phase 3 | Jul 31, 2019 | Vanda Pharmaceuticals |
| NCT03772340 | Phase 2 | Dec 31, 2018 | Vanda Pharmaceuticals |
| NCT03568331 | Phase 3 | Jun 30, 2018 | Vanda Pharmaceuticals |
| NCT02970968 | Phase 2 | Nov 1, 2016 | Vanda Pharmaceuticals |
| NCT02651714 | Phase 2 | Jan 1, 2016 | Vanda Pharmaceuticals |
| NCT02621385 | Phase 1 | Nov 1, 2015 | Cross Research S.A., Vanda Pharmaceuticals |
| NCT02004041 | Phase 2 | Dec 1, 2013 | Vanda Pharmaceuticals |
| NCT01919944 | Phase 1 | Aug 1, 2013 | Cross Research S.A., Vanda Pharmaceuticals |
| NCT00805441 | Phase 2 | Dec 1, 2008 | Eli Lilly |
| NCT00310427 | Phase 2 | Mar 1, 2006 | Eli Lilly, National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| NCT00191022 | Phase 2 | Dec 1, 2004 | Eli Lilly |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals | For profit | 18 | 18 | 4 | 2013 |
| Eli Lilly | For profit | 3 | 2 | 1 | 2004 |
| Cross Research S.A. | For profit | 2 | 0 | 1 | 2013 |
| Mayo Clinic | Academic/Hospital | 2 | 0 | 2 | 2021 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 1 | 1 | 1 | 2006 |
5 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Vanda Pharmaceuticals | For profit | MKTG | Dec 30, 2025 |